Fleshner NE - Search Results

1

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

Al-Ezzi EM, Alqaisi HA, Iafolla MAJ, Wang L, Sridhar SS, Sacher AG, Fallah-Rad N, Jiang DM, Watson GA, Catton CN, Warde PR, Hamilton RJ, Fleshner NE, Zlotta AR, Hansen AR. Al-Ezzi EM, et al. Among authors: fleshner ne. Cancer Med. 2021 Sep;10(17):5775-5782. doi: 10.1002/cam4.4125. Epub 2021 Jul 13. Cancer Med. 2021. PMID: 34254464 Free PMC article.

2

Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder.

Fleshner N, Garland J, Moadel A, Herr H, Ostroff J, Trambert R, O'Sullivan M, Russo P. Fleshner N, et al. Cancer. 1999 Dec 1;86(11):2337-45. Cancer. 1999. PMID: 10590376

3

Controversies in the management of testicular seminoma.

Fleshner N, Warde P. Fleshner N, et al. Semin Urol Oncol. 2002 Nov;20(4):227-33. doi: 10.1053/suro.2002.36979. Semin Urol Oncol. 2002. PMID: 12489054 Review.

4

Is there age bias in the treatment of localized prostate carcinoma?

Alibhai SM, Krahn MD, Cohen MM, Fleshner NE, Tomlinson GA, Naglie G. Alibhai SM, et al. Among authors: fleshner ne. Cancer. 2004 Jan 1;100(1):72-81. doi: 10.1002/cncr.11884. Cancer. 2004. PMID: 14692026 Free article.

5

Antioxidants block prostate cancer in lady transgenic mice.

Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Venkateswaran V, et al. Among authors: fleshner ne. Cancer Res. 2004 Aug 15;64(16):5891-6. doi: 10.1158/0008-5472.CAN-04-0690. Cancer Res. 2004. PMID: 15313934

6

A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study.

Bunting PS, Neuman J, Goel V, Fleshner N, Kopec J, Levers P, Warde P. Bunting PS, et al. J Clin Epidemiol. 2005 Jun;58(6):639-44. doi: 10.1016/j.jclinepi.2004.10.014. J Clin Epidemiol. 2005. PMID: 15878478

7

Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.

Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, Levers P, Fleshner N. Kopec JA, et al. J Urol. 2005 Aug;174(2):495-9; discussion 499. doi: 10.1097/01.ju.0000165153.83698.42. J Urol. 2005. PMID: 16006879

8

Management of low-stage testicular seminoma.

Neill M, Warde P, Fleshner N. Neill M, et al. Urol Clin North Am. 2007 May;34(2):127-36; abstract vii-viii. doi: 10.1016/j.ucl.2007.02.009. Urol Clin North Am. 2007. PMID: 17484918 Review.

9

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.

Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Kulkarni GS, et al. Among authors: fleshner ne. Cancer. 2007 Jun 15;109(12):2432-8. doi: 10.1002/cncr.22712. Cancer. 2007. PMID: 17497649 Free article.

10

Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.

Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T. Fleshner N, et al. Prostate Cancer Prostatic Dis. 2008;11(1):46-52. doi: 10.1038/sj.pcan.4500982. Epub 2007 Jul 3. Prostate Cancer Prostatic Dis. 2008. PMID: 17607304 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

644 results

Search Page

Filters